Prothrombin G20210A: the other inherited clotting variant

Genetics explainer · Updated June 2026

A quick tour of the clotting cascade

To see what this variant does, it helps to picture how blood clots in the first place. When a vessel is injured, your body runs a chain reaction called the coagulation cascade — a relay of proteins (the clotting factors), each one activating the next. The point of the cascade is to build a clot exactly where and when it is needed, then stop. It is a balancing act: pro-clotting factors push in one direction, and a set of natural brakes — proteins that switch factors off — push back so a clot stays local and does not spread.

The last major step of that relay is the conversion of prothrombin into thrombin, the enzyme that turns dissolved fibrinogen into fibrin, the mesh that holds a clot together. Prothrombin sits near the finish line: the more of it circulating, the more thrombin can be generated once the cascade fires, and the more readily a clot forms. Inherited clotting variants matter because they nudge this balance a little toward the clotting side and keep it there.

What prothrombin G20210A does

Prothrombin — also called Factor II — is the protein your body converts into thrombin. The G20210A variant is a single-letter change in the F2 gene, and in raw data it is reported at rs1799963. What makes it unusual is where the change sits. It does not alter the prothrombin protein itself; instead it lands in a non-coding region (the 3′ untranslated region) that influences how efficiently the gene's message is processed. The practical result is that carriers tend to make and carry slightly more prothrombin than non-carriers.

Follow that through the cascade and the logic is simple: more prothrombin on hand means more thrombin can be produced when clotting is triggered, so clotting becomes a little easier to start and a little harder for the body's brakes to rein in. The change is quantitative and modest — it shifts a set point, it does not flip a switch. That is why so many carriers go their whole lives without a clot.

The conditions it is associated with are the same family as Factor V Leiden: venous thromboembolism (VTE), mainly deep vein thrombosis (DVT) in the legs and pulmonary embolism (PE) in the lungs — clots that form in veins rather than the arterial clots behind most heart attacks and strokes.

How much it actually raises risk

This is the part worth keeping in proportion. Prothrombin G20210A is generally considered a modest risk factor.

Two things keep this grounded. First, relative risk is not absolute risk: a two-to-threefold increase on a small baseline is still a small number, and the vast majority of carriers never have a clot. Second, clotting risk is rarely about one gene — it climbs around specific triggers and falls again when they pass.

Heterozygous versus homozygous

The AG result — one variant copy inherited from one parent — is by far the common form, and it is the one attached to that modest, mostly-latent increase in risk. The AA result — two copies — is uncommon and generally sits at a higher level, but even here the numbers reflect a relative increase against a low baseline, and interpreting a homozygous result is precisely the kind of thing a clinician does in the context of your whole history rather than something to read off a table. Neither result is a diagnosis, and neither on its own tells you a clot is coming. What both do is establish a standing risk factor — a piece of background that becomes relevant mainly when a trigger stacks on top of it.

The contexts that matter

The variant matters most when it overlaps with a situation that raises clotting risk on its own:

• Surgery and hospital stays — major operations and the immobility that follows are classic triggers, which is exactly why surgical teams ask about clotting history.
• Pregnancy and the weeks after birth — pregnancy naturally shifts the body toward clotting, and a known variant is useful context for an obstetric team.
• Estrogen-containing medication — combined hormonal contraceptives and some hormone therapies add their own clotting risk on top of any inherited factor.
• Long immobility — extended bed rest or very long-haul travel.
• Smoking and increasing age — both raise baseline clotting risk over time and add to whatever an inherited factor contributes.
• Co-inherited clotting variants — carrying Factor V Leiden as well pushes the picture further, which we cover in the next section.

These factors are multipliers, not a checklist that guarantees a clot. The reason they matter is that inherited variants are largely quiet on an ordinary day; risk becomes real when a trigger stacks on top of a standing factor. None of this means a carrier must avoid surgery, pregnancy, travel, or hormonal medication. It means the variant is a useful piece of information to put on the table so that a clinician — an obstetric team, a surgical team, or the doctor discussing contraception — can weigh the whole picture and decide whether anything about the plan should change.

How it relates to Factor V Leiden

These two are siblings, not twins. They act on different proteins in the same clotting cascade and are inherited independently — you can carry one, both, or neither. Factor V Leiden makes Factor V resistant to being switched off, so one of the cascade's brakes works less well; prothrombin G20210A tends to raise prothrombin levels, so there is more raw material feeding the clotting side. One weakens a brake, the other adds fuel — different mechanisms pointing the same direction.

Because the effects stack, carrying both variants pushes risk higher than either alone, and the combination is exactly the sort of thing a clinician wants to weigh in context rather than have anyone infer from two lines in a raw-data file. It is worth stressing that this is still about relative risk layered on a baseline, not a verdict — plenty of people carry both variants without ever having a clot. But the combined picture is a genuinely good reason to bring the whole result to a doctor rather than reading it piecemeal. If you have not read it yet, our companion explainer on Factor V Leiden (rs6025) covers the other half of the pair.

When it is worth talking to a clinician

You do not need a doctor's appointment simply because a common variant appears in a raw file. But there are a handful of situations where raising it is genuinely worthwhile — less because the variant is alarming and more because these are the moments when clotting risk is already on a clinician's mind:

• You are planning a pregnancy, or are pregnant. Pregnancy and the weeks after birth shift the body toward clotting on their own; a known variant is useful context for an obstetric team.
• You are choosing or reviewing contraception or hormone therapy. Estrogen-containing options add their own clotting risk, so the variant is worth mentioning in that conversation — without changing anything on your own first.
• You have surgery, a hospital stay, or a long period of immobility ahead. Surgical teams ask about clotting history precisely because these are classic triggers.
• You, or a close relative, have had an unexplained blood clot — a DVT or PE without an obvious cause, or clots at a young age.
• There is a family history of clotting variants or thrombophilia. Because these variants are inherited, a known family result changes how your own is interpreted.

In each case the move is the same: bring the information to a professional who can order proper testing and weigh it against your history. The variant is a prompt for a conversation, not an instruction to act.

Why raw data is not diagnostic

It is worth being blunt about the limits of the file itself. Consumer DNA kits from 23andMe and AncestryDNA use genotyping arrays — they check specific positions rather than reading your genome fully — and they are built for ancestry and general interest, not clinical diagnosis. A single position such as rs1799963 can occasionally be miscalled, and a raw-data readout carries none of the quality control, confirmatory testing, or interpretation that a clinical thrombophilia workup does.

Clotting risk is also a medical judgment, not a lookup. It depends on your personal and family history, other risk factors, any other variants, and the specific situations ahead of you — the kind of synthesis a clinician is trained to do and a single line in a spreadsheet cannot. That is why a positive raw-data result should always be confirmed clinically before it means anything, and why any decision that follows belongs with a doctor.

What to do with the result

If prothrombin G20210A flags as a carrier result — or if you have a personal or family history of clots regardless of what your file says — the right next step is a clinician and, where appropriate, a confirmatory clinical test, not a self-assessment. Knowing your status is genuinely useful information to bring to that conversation; acting on it is a job for your doctor.

There are, though, a few sensible and entirely non-clinical things a carrier can do. You can note the result so it is on hand when a doctor asks about clotting history, and mention it proactively ahead of surgery, pregnancy planning, or a conversation about contraception. You can be aware of the ordinary, everyone-benefits measures around known triggers — moving and staying hydrated on very long flights, taking movement breaks during long stretches of immobility — which are good practice for anyone, carrier or not. And you can learn the warning signs of a clot so you would seek care promptly: a swollen, painful, warm calf (a possible DVT), or sudden shortness of breath, chest pain, or coughing (a possible PE) warrant urgent medical attention. What a carrier should not do is start, stop, or adjust any medication — anticoagulants, the pill, hormone therapy — on the strength of a raw-data result. Those decisions belong to a clinician who knows your full history.

For the full genotype breakdown, see prothrombin G20210A (F2) in our gene library. To understand the other common inherited clotting variant, read Factor V Leiden in your raw data, or browse the rest of the Quanome blog.

Frequently asked questions

What is prothrombin G20210A?

It is a common inherited variant in the F2 gene, which codes for prothrombin (also called Factor II), a protein in the blood-clotting cascade. The variant tends to raise prothrombin levels slightly, which nudges the balance toward clotting. It is one of the two most common inherited clotting variants, alongside Factor V Leiden.

How much does it raise clotting risk?

For most carriers the increase is modest. Having one copy is associated with a roughly 2–3x higher relative risk of venous clots compared with non-carriers. But relative risk is not the same as absolute risk — the great majority of carriers never have a clot. Risk rises mainly around triggers like major surgery, long immobility, pregnancy, and estrogen-containing medication.

How is it different from Factor V Leiden?

They affect different proteins in the same clotting cascade and are inherited independently. Factor V Leiden makes Factor V resistant to being switched off; prothrombin G20210A tends to raise prothrombin levels. Carrying both is possible and pushes risk higher, which is one reason a clinician looks at the whole picture rather than a single marker.

Is a raw-data result a diagnosis?

No. Consumer raw data is a starting point, not a clinical test. A single-marker readout can be misread, and clotting risk is a medical matter that depends on far more than one gene. If this variant flags in your file, or you have a personal or family history of clots, see a clinician for confirmatory testing and advice.

Which SNP is prothrombin G20210A in my raw data?

It is reported at rs1799963 in the F2 gene. In 23andMe or AncestryDNA raw data you may see it labelled by that rsID. A single genotyping-array call is not a clinical diagnosis — if it flags, the responsible step is confirmatory testing ordered by a clinician, not a decision made from the raw file alone.

I carry the variant and want to start or stop the pill (or HRT). What should I do?

Talk to your doctor before changing anything. Estrogen-containing contraceptives and some hormone therapies add clotting risk on top of any inherited factor, so a known variant is genuinely useful context for that conversation. But the decision — whether the variant changes your options at all — is a clinical judgment that weighs your full history. Do not start or stop any medication on the basis of a raw-data result.

I'm a carrier and planning a pregnancy or surgery. Does that change anything?

Possibly, and that is exactly why it is worth raising. Pregnancy, the postpartum weeks, and major surgery all shift the body toward clotting on their own, so an obstetric or surgical team may want to know your status. Bring it up in advance so they can weigh the whole picture and decide whether any precautions apply. This is information to hand your care team, not something to manage yourself.

Should a carrier take blood thinners just in case?

No — not on the basis of a variant alone. Anticoagulants carry their own risks and are prescribed for specific clinical reasons, never as a precaution triggered by a raw-data result. Whether any preventive measure makes sense is a decision for a clinician who knows your history. Never start, stop, or adjust a blood thinner on your own.